Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $158.3 million.

  • CytomX Therapeutics' Liabilities and Shareholders Equity rose 1386.74% to $158.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $552.3 million, marking a year-over-year decrease of 1932.85%. This contributed to the annual value of $120.5 million for FY2024, which is 4026.87% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Liabilities and Shareholders Equity of $158.3 million as of Q3 2025, which was up 1386.74% from $175.1 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Liabilities and Shareholders Equity ranged from a high of $434.2 million in Q1 2021 and a low of $98.5 million during Q1 2025
  • Over the past 5 years, CytomX Therapeutics' median Liabilities and Shareholders Equity value was $221.2 million (recorded in 2023), while the average stood at $236.5 million.
  • Data for CytomX Therapeutics' Liabilities and Shareholders Equity shows a peak YoY increase of 1386.74% (in 2025) and a maximum YoY decrease of 4666.81% (in 2025) over the last 5 years.
  • Over the past 5 years, CytomX Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $339.4 million in 2021, then dropped by 23.13% to $260.9 million in 2022, then decreased by 22.65% to $201.8 million in 2023, then tumbled by 40.27% to $120.5 million in 2024, then soared by 31.3% to $158.3 million in 2025.
  • Its last three reported values are $158.3 million in Q3 2025, $175.1 million for Q2 2025, and $98.5 million during Q1 2025.